RLS (USA) Inc.

RLS (USA) Inc., a foreign-owned radiopharmacy company headquartered in Lake Mary, Florida, supplies specialized nuclear medicine diagnostic and therapeutic radiopharmaceuticals to the Department of Veterans Affairs and Defense Health Agency as a prime contractor, competing in full-and-open federal healthcare procurements on technical capability, past performance, and price. The company is a subsidiary of Telix Pharmaceuticals US Inc. and operates 31 radiopharmacy facilities across 18 states, enabling time-sensitive delivery of medical isotopes and diagnostic imaging agents to VA medical centers and military treatment facilities nationwide. RLS (USA) Inc. does not hold small business designations and competes predominantly outside set-asides, though several awards carry Total Small Business set-aside designations (most recently a $157,346.50 order from VISN 17 for Locametz kits in October 2025).

The company's capability portfolio centers on brand-name and generic radiopharmaceuticals including technetium-99m derivatives, gallium-67, fluorodeoxyglucose F-18, thallium-201, iodine isotopes (I-123, I-131), indium-111, and specialty agents such as Gallium-68 Dotatate (NETSPOT) and locametz (gallium Ga-68 gozetotide). Recent representative work includes a $4,998,603.38 single-award indefinite delivery contract with VISN 17 (awarded September 2024, extending through September 2029) for fluorodeoxyglucose F-18 and general radiopharmaceuticals supporting the Central Texas Veterans Health Care System; a $6,992,473.02 single-award IDIQ with VISN 22 (awarded April 2026) for radiopharmaceutical supply to Phoenix and Tucson healthcare systems with guaranteed minimums of $250,000 to $1,000,000 per delivery order; and a $3.7 million definitive contract with VISN 7 (awarded July 2024, extending through July 2029) for single-photon emission radiopharmaceuticals including pertechnetate, pyrophosphate, and medronate to the Atlanta VA Health Care System.

Customer concentration is heavily weighted toward the Veterans Health Administration across multiple VISN networks and the Defense Health Agency, with the top five customers accounting for 77 percent of recent awards. VISN 17 and VISN 22 dominate both volume and potential value, each carrying $14.6 million in combined potential value across 17 and 8 awards respectively. VISN 7, VISN 21, and VISN 20 round out the top five by potential value, contributing $10.7 million, $9.8 million, and $7.7 million respectively. The Defense Health Agency accounts for 21 awards but only $6 million in combined potential value, reflecting smaller task-order magnitude relative to VA networks. Activity has grown from 16 awards in 2024 to 23 in 2025, with 15 awards in 2026 year-to-date. Fourteen awards (combined potential value $10.3 million) reach ultimate completion within the next twenty-four months, creating recompete exposure primarily on VISN 17, VISN 22, and VISN 21 vehicles.

RLS (USA) Inc. holds a portfolio of single-award indefinite delivery contracts and blanket purchase agreements across the VA and Defense Health Agency. Named IDIQs include a $6 million vehicle with VISN 20 (January 2026 through December 2030) for radiopharmaceuticals for nuclear medicine patients; a $2.5 million IDIQ with VISN 21 (April 2025 through March 2030) for radiopharmaceutical supply to the Northern California Health Care System at Mather; a $2.162 million IDIQ with VISN 5 (April 2025 through March 2030); a $2.182 million IDIQ with VISN 21 (April 2025 through March 2030) for non-PET radiopharmaceuticals; a $1.9 million blanket purchase agreement with the Defense Health Agency (October 2024 through September 2029) for 31 radiopharmaceutical products and services at Naval Medical Center San Diego; and a $1.2 million IDIQ with VISN 21 (April 2025 through March 2030) for radiopharmaceutical supplies. The company also maintains smaller vehicles including a $538,493.10 Total Small Business set-aside IDIQ with VISN 2 (August 2024 through July 2029) for NETSPOT GA-68 supply. Across these vehicles, task orders are placed on an as-needed basis for next-business-day or same-day delivery, with many contracts requiring compliance with Nuclear Regulatory Commission licensure, USP 797 standards, and firm fixed-price pricing structures. The vendor competes under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC 6505 (Drugs and Biologicals), classified across 96 prime awards with zero subcontract activity in the source data.

RLS is committed to maintaining high standards in the industry, from agent compounding to customer delivery. Our continuous focus on safety has created an innovative WBC labeling process that supports patient blood integrity. RLS (Radioisotope Life Sciences) sees itself as a key role player to facilitate the entry of new drugs and the installation of state of the art imaging equipment into the practice of health care. We also commit to expanding the market through alternative methods of production for Tc-99m and Ga-68. RLS maintains high-quality standards by routinely upgrading operational procedures to provide the best available practices. One of our key services is the procedure of radiolabeling autologous leukocytes (WBC labeling process). We have also implemented a uniquely keyed locking system to ensure limited access during the entire labeling process.